A Systematic Review of Time and Resource Use Costs of Subcutaneous Versus Intravenous Administration of Oncology Biologics in a Hospital Setting.

Pharmacoecon Open · 2023 · PMC9395845 · PMID 35996066

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

However, six European publications reported similar percentage savings in direct costs and most publications showed a trend for cost saving with SC versus IV administration of trastuzumab.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.